Shengsheng Cold Chain Submits Hong Kong IPO Application on July 22, Eyes Largest Market Position in China

According to Hong Kong Exchanges and Clearing (HKEX) disclosure on July 22, Shanghai Shengsheng Medical Pharmaceutical Cold Chain Technology Co., Ltd. (Shengsheng Cold Chain) submitted its application for listing on the HKEX main board. China International Capital Corporation Limited and Guoyuan Securities (Hong Kong) Limited serve as joint sponsors.

According to the prospectus, Shengsheng Cold Chain is China's leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences sectors, with core focus on clinical trial temperature-controlled supply chain services, complemented by commercial medical product temperature-controlled supply chain services and development of temperature-controlled equipment and materials. By 2025 revenue, the company ranks as China's largest pharmaceutical and life sciences temperature-controlled supply chain service provider and is the only Chinese enterprise among the top ten global clinical trial temperature-controlled supply chain service providers, according to Frost & Sullivan.